Jazz Pharmaceuticals insider sale: 3,731 vested shares to be sold on NASDAQ

Rhea-AI Filing Summary

Form 144 notice for Jazz Pharmaceuticals (JAZZ) reports a proposed sale of 3,731 common shares on NASDAQ with an aggregate market value of $417,872. The form lists total shares outstanding as 60,658,809 and an approximate sale date of 08/08/2025.

The shares were acquired on 08/07/2025 through restricted stock vesting from the issuer and the form records payment/compensation as of 08/07/2025. ETRADE FINANCIAL CORPORATION is named as the broker. The filer indicates no securities sold in the past three months and attests they are not aware of undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR: Routine small insider sale of newly vested restricted shares; unlikely to move market or indicate material change.

The notice documents a proposed disposition of 3,731 shares valued at $417,872, acquired by restricted stock vesting the day before the planned sale. With 60,658,809 shares outstanding recorded on the form and no reported sales in the prior three months, this filing appears operational and compensation-driven rather than a signal of company-specific problems. Disclosure follows Rule 144 mechanics and includes the broker designation.

Corporate Governance Expert

TL;DR: Disclosure is consistent with Rule 144 requirements; attestation included and transaction recorded as compensation.

The form indicates the shares resulted from restricted stock vesting and that payment was recorded as compensation. The filer’s attestation that they do not possess undisclosed material information is present on the form. Broker information is provided. There are no reported prior sales in the past three months, suggesting this is a routine reporting of an insider compensation event.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	ETRADE FINANCIAL CORPORATION ETRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 30005	3731	417872.00	60658809	08/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	08/07/2025	RESTRICTED STOCK VESTING	ISSUER			3731	08/07/2025	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the JAZZ Form 144 report?

The form reports a proposed sale of 3,731 common shares of Jazz Pharmaceuticals valued at $417,872 on NASDAQ.

When were the shares acquired according to the filing?

The shares were acquired on 08/07/2025 via restricted stock vesting from the issuer, with payment listed as 08/07/2025.

Who is the broker listed on the Form 144 for JAZZ?

ETRADE FINANCIAL CORPORATION is named as the broker on the filing.

Has the filer sold other securities of JAZZ in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

How many JAZZ shares are outstanding according to the form?

The form lists 60,658,809 shares outstanding.